A Phase 4 interventional study of Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL in Drug Interactions, Primary Prevention and Cardiometabolic Syndrome, sponsored by University of California, San Diego. Recruiting at 1 site in United States. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-11-10.
Sponsored by University of California, San Diego · Phase 4, Interventional, and Treatment
…and 4 more changes, on the record history on ClinicalTrials.gov ↗
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 578 studies in Metabolic Syndrome with a site in United States — 62 open to participants now, 84 under way, 3 of them phase 3. Metabolic Syndrome · United States.
Among the 578 studies in Metabolic Syndrome with a site in United States, this one is the 117th largest by planned enrollment of the 490 interventional ones that give a count, is one of 18 that started in 2025, is one of 44 in phase 4, reaches primary completion later than 56 of the 82 other live ones, and was the 549th registered.
2,119 studies on the registry are indexed under Metabolic Syndrome; 350 are open to participants now.
Browse Metabolic Syndrome studies →62 of the 578 studies in Metabolic Syndrome with a site in United States are open now. Recruiting first, the newest first:
Arizona State University · Sites in United States
Ages 18–65
Stanford University · Sites in United States
Ages 18–80
Northwell Health · Sites in United States
Ages 21–75
Longevity Metrics, Inc. · Sites in United States
Ages 18+ · Healthy volunteers
University of Virginia · Sites in United States
Ages 6–18
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 234 Metabolic Syndrome studies recruiting now, 70 (30%) set no upper age limit and 135 (58%) stop at 75 or younger; 20 take children under 18; 81 take healthy volunteers.
This study: 18 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
578 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 35 · Phase 2 68 · Phase 3 20 · Phase 4 44
First in 1982; this study’s year is marked. 18 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is above the median of 60 across 1,574 interventional studies indexed under Metabolic Syndrome.
Median enrollment 48 across the 490 interventional studies, 141 across the 86 observational. Of the 443 that completed or were terminated, 136 (31%) have results posted.
This tab as a report to print or save as PDF → With an account.
47 of 578 have an industry lead sponsor. The 10 most frequent:
University of California, San Diego is the lead sponsor of 980 studies on the registry; 194 are open to participants now.
Of its 113 completed or terminated interventional studies of FDA-regulated products, 71 (63%) have results posted.
University of California, San Diego has 9 studies filed under Metabolic Syndrome — fewer than ten, so there is no comparison to draw.
28 of the studies in Metabolic Syndrome with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07625332Phase 3Northwell HealthPilot Study of Galantamine to Treat Metabolic Syndrome in People With Chronic Traumatic Spinal Cord Injury (SCI) | 2027-08 |
| NCT07095426Ball State UniversityImpact of Supplemental Fiber on Gut and Vascular Health Related in Obesity Phenotypes | 2026-11 |
| NCT04974554Medical University of South CarolinaFIT Families Multicomponent Obesity Intervention for African American Adolescents | 2026-11-30 |
| NCT05943626University of UtahCircadian Intervention to Improve Cardiometabolic Health | 2026-12 |
| NCT05654142University of Illinois at ChicagoThe PIVOT Trial: Project on EHR-Integrated Lifestyle Interventions for Adults Aged Fifty and Older | 2026-12-31 |
Add all 28 to your calendar (.ics) → With an account.
Among the 578 studies in Metabolic Syndrome with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Polypharmacy and drug-drug interactions often limit statin optimization, including in a population of patients prescribed cytochrome P3A4 inhibitors such as, immunosuppressive agents, protease inhibitors, and antifungals. These patients frequently have autoimmune conditions or rheumatologic disorders that require complex drug regimens and are often on low-dose statin therapy or no statin at all, resulting in suboptimal LDL levels despite increased cardiovascular (CV) risk.
There is an unmet clinical need to improve LDL levels in this vulnerable patient population, which faces increased CV risk due to underlying conditions that also contribute to polypharmacy and multiple drug-drug interactions. This study is a randomized, open-label trial evaluating subcutaneous inclisiran plus standard of care for LDL-C lowering in high-risk primary prevention patients with multiple comorbidities (e.g., type II diabetes, liver disease, chronic kidney disease, autoimmune disease, solid-organ transplant, etc.) who are taking five or more medications in which drug-drug interactions may prevent optimization of statin therapy.
This is an investigator-initiated, single-site, open-label, randomized trial. The investigators will enroll up to 100 high-risk primary prevention patients with at least one comorbidity and an indication for additional lipid control (such as Type II diabetes with A1c ≤ 8.5%, subclinical atherosclerosis, or increased 10-year ASCVD risk). Patients will be randomized 1:1 to the inclisiran arm (n ≥ 50) with standard of care or standard of care alone (n ≥ 50).
The study will consist of five study visits (screening, baseline, 3 months, 9 months, and 12 months). Patients in the inclisiran arm will receive a subcutaneous injection of inclisiran 284 mg for three doses (baseline, 3 months, and 9 months following randomization) as add-on therapy. LDL-C (the primary endpoint) along with other biomarkers will be measured at screening, baseline (inclisiran dose #1), 3 months (inclisiran dose #2), 9 months (inclisiran dose #3), and 12 months (labs only). Patients will also undergo medical history and medication review at each visit. Surveys will be completed at each visit during the study period.
Patients in the control arm (standard of care) will continue with their current lipid-lowering therapy. No adjustments will be made to lipid-lowering therapy during the course of the study. Participants will be aware of the group to which they have been randomized.
The primary objective is to determine the efficacy of inclisiran for LDL-C lowering in high-risk primary prevention patients with multiple comorbidities (e.g., type II diabetes, autoimmune disease, liver disease, chronic kidney disease, solid-organ transplant) who are taking five or more medications in which drug-drug interactions may prevent optimization of statin therapy.
The criteria were revised on the registry on Nov 10, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
To be eligible to participate in this study, individuals must meet all of the following criteria:
Meet at least one of criteria a, b, or c:
Evidence of subclinical atherosclerosis:
Exclusion Criteria:
Individuals who meet any of the following criteria will be excluded from participation in this study:
Have a history of ASCVD, defined as history of myocardial infarction, atherosclerotic ischemic stroke, (TIA) of atherosclerotic ischemic origin, coronary artery bypass graft (CABG), coronary/carotid/peripheral artery/aortic stent for atherosclerotic disease, or peripheral artery disease diagnosed via imaging or ankle-brachial index).
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients will continue the standard of care for lipid lowering as deemed appropriate by their medical team, no changes to lipid lowering therapy are permitted during the study.
Patients in the intervention arm will be treated with a subcutaneous injection of inclisiran 284mg for three doses (baseline visit, 3 month, then 9 month visit) as add-on therapy to the standard of care for lipid lowering as determined by their medical team.
Drug: Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL
The intervention arm will receive subcutaneous injection of inclisiran 284mg at the baseline visit, 3 month and 9 month visit.
Change of LDL-Cholesterol
Percent Change in LDL-C from baseline to month 12 of treatment with inclisiran as add on to background lipid-lowering therapy that includes maximally tolerated statin.
Time frame: 12 months
Change in Atherogenic Lipid Burden
Absolute and percent change in LDL particle number, apo B, non-HDL, and small LDL particle number, lipoprotein(a), from baseline (Day 1) to month 12 of treatment with inclisiran
Time frame: 12 months
Patient-Reported Experience
Patient-reported outcomes and experiences determined by surveys at each visit (the Standardized Treatment Satisfaction Questionnaire for Medication and study-specific inclisiran satisfaction questionnaire).
Time frame: 12 months
Incidence of Adverse Events
Incidence of adverse events occurring during treatment with inclisiran.
Time frame: 12 months
Plan to share: No — Individual participant data (IPD) is not expected to be shared due to privacy concerns, institutional policies, and regulatory considerations. However, the Principal Investigator may determine that certain de-identified data may be shared with other researchers on a case-by-case basis, subject to appropriate approvals and data use agreements.
Started Apr 2025 (actual). Primary completion is estimated for Jun 2028, 37 months after the start.
Of 32 phase 4 interventional studies under Metabolic Syndrome, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 57. This study's planned 37 months is above that.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 10, 2026: primary completion Dec 2026 → Jun 2028 and completion Mar 2027 → Sep 2028.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
…and 4 more changes, on the record history on ClinicalTrials.gov ↗
…and 4 more changes, on the record history on ClinicalTrials.gov ↗
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Inclisiran
University of California, San Diego →